Valuation: Exelixis, Inc.

Market Cap 13.3B 11.39B 10.65B 9.75B 18.31B 1,273B 18.56B 126B 49.07B 639B 49.95B 48.86B 2,113B P/E 2026 *
16.7x
P/E 2027 * 14.2x
Enterprise Value 12.56B 10.75B 10.06B 9.21B 17.28B 1,202B 17.52B 119B 46.32B 603B 47.15B 46.12B 1,995B EV / Sales 2026 *
4.92x
EV / Sales 2027 * 4.07x
Free-Float
98.15%
Yield 2026 *
-
Yield 2027 * -
1 day+0.73%
1 week+6.86%
Current month+1.98%
1 month-2.61%
3 months+8.38%
6 months+23.95%
Current year+23.39%
1 week 50.8
Extreme 50.805
54.68
1 month 49.97
Extreme 49.97
56.95
Current year 39.71
Extreme 39.71
57.57
1 year 33.76
Extreme 33.755
57.57
3 years 18.64
Extreme 18.64
57.57
5 years 14.87
Extreme 14.87
57.57
10 years 10.04
Extreme 10.04
57.57
Manager TitleAgeSince
Chief Executive Officer 65 22/07/2010
Director of Finance/CFO 58 15/07/2015
Chief Operating Officer 63 01/02/2016
Director TitleAgeSince
Director/Board Member 70 01/02/2004
Director/Board Member 82 01/08/2004
Chairman 77 01/01/1998
Date Insider Type Main position Quantity % Market Cap.
8/10/26 A Sell

Director

-9,812 0.0039%
5/27/26 A Free

Director

8,367 0.0033%
2/26/26 A Free

General Counsel

23,119 0.0086%
Change 5-day change 1-year change 3-year change Capi.($)
+0.73%+6.86%+42.84%+156.30% 13.3B
-3.00%+0.33%+77.39%+109.41% 73.96B
+1.90%+19.57%+60.16%+101.03% 64.66B
+0.55%-0.44%-2.84%+478.79% 27.32B
+5.12%+26.54%+4.73%+5.63% 27.86B
+2.74%+11.55%+66.56%+27.34% 25.97B
+0.47%+6.22%+39.36%-12.38% 19.98B
+1.82%-3.11%+245.72%+423.83% 17.84B
+0.94%+2.38%+24.83%+552.12% 16.24B
-0.41%+1.78%+331.24%+208.24% 12.36B
Average +1.09%+5.76%+89.00%+205.03% 29.95B
Weighted average by Cap. +0.64%+6.48%+72.23%+165.30%

Financials

2026 *2027 *
Net sales 2.55B 2.18B 2.04B 1.87B 3.51B 244B 3.56B 24.14B 9.41B 123B 9.58B 9.37B 405B 2.87B 2.46B 2.3B 2.1B 3.95B 275B 4B 27.16B 10.59B 138B 10.78B 10.54B 456B
Net income 821M 703M 657M 602M 1.13B 78.52B 1.14B 7.77B 3.03B 39.42B 3.08B 3.01B 130B 974M 834M 780M 714M 1.34B 93.23B 1.36B 9.22B 3.59B 46.8B 3.66B 3.58B 155B
Net Debt -744M -638M -596M -546M -1.02B -71.24B -1.04B -7.04B -2.75B -35.76B -2.8B -2.73B -118B -1.62B -1.39B -1.3B -1.19B -2.23B -155B -2.26B -15.35B -5.98B -77.94B -6.09B -5.96B -258B
Logo Exelixis, Inc.
Exelixis, Inc. is an oncology company. The Company has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. It is also advancing and evolving its product pipeline portfolio, including its lead investigational asset, zanzalintinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma, for previously treated hepatocellular carcinoma and for previously treated, radioactive iodine-refractory differentiated thyroid cancer, and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer. The Company's other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved the treatment of hypertension in Japan.
Employees
1,077
Date Price Change Volume
21/08/26 $54.08 +0.73% 1,949,642
20/08/26 $53.69 -1.29% 1,950,664
19/08/26 $54.39 +2.39% 2,503,640
18/08/26 $53.12 +1.53% 1,290,526
17/08/26 $52.32 +2.11% 2,372,576
Trader
Investor
Global
Quality
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
20
Last Close Price
53.69USD
Average target price
53.00USD
Spread / Average Target
-1.29%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. EXEL Stock